1924 - Outpatient Treatment With the SARS-CoV-2–Neutralizing Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) for Preventing COVID-19 Hospitalizations in the Phase 3 TACKLE Trial

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

HM

Hugh Montgomery, MD

University College London
London, England, United Kingdom
FP

Francisco Padilla, MD

Centro de Investigación en Cardiología y Metabolismo
Guadalajara, Jalisco, Mexico
KK

Kenneth Kim, MD

ARK Clinical Research
Long Beach, California, United States
Jesus Abraham Simón Campos, MD

DIRECTOR
Köhler & Milstein Research/Hospital Agustín O’Horán
Mérida, Yucatan, Mexico
DA

Douglas Arbetter, MPH

AstraZeneca
Waltham, Massachusetts, United States
KP

Kelly W. Padilla, PharmD

AstraZeneca
Durham, North Carolina, United States
VR

Venkatesh P. Reddy, PhD

AstraZeneca
Cambridge, England, United Kingdom
SS

Seth Seegobin, PhD

AstraZeneca
Cambridge, England, United Kingdom
KS

Katie Streicher, PhD

AstraZeneca
Gaithersburg, Maryland, United States
RV

Rolando M. Viani, PhD

AstraZeneca
Gaithersburg, Maryland, United States
GK

Gavin CKW Koh, PhD

AstraZeneca
Cambridge, England, United Kingdom
ME

Mark T. Esser, PhD

Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patient
AstraZeneca
Gaithersburg, Maryland, United States